Growth hormone research society workshop summary: Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome

Cheri L. Deal, Michèle Tony, Charlotte Hoÿbye, David B. Allen, Maïth́e Tauber, Jens Sandahl Christiansen, Geoffrey R. Ambler, Renaldo Battista, Véronique Beauloye, Glenn Berall, Beverly M K Biller, Merlin G. Butler, Suzanne B. Cassidy, Kazuo Chihara, Pinchas Cohen, Maria Craig, Stense Farholt, Mireille Goetghebeur, Anthony P. Goldstone, Tiziana GreggiGraziano Grugni, Anita C. Hokken-Koelega, Gudmundur Johannsson, Keegan Johnson, Alex Kemper, John J. Kopchick, Saul Malozowski, Jennifer Miller, Harriette R. Mogul, Françoise Muscatelli, Ricard Nergårdh, Robert D. Nicholls, Sally Radovick, M. Sara Rosenthal, Ilkka Sipilä, Jean Eric Tarride, Annick Vogels, Michael J. Waters

Research output: Contribution to journalArticle

Abstract

Context: Recombinant human GH (rhGH) therapy in Prader-Willi syndrome (PWS) has been used by the medical community and advocated by parental support groups since its approval in the United States in 2000 and in Europe in 2001. Its use in PWS represents a unique therapeutic challenge that includes treating individuals with cognitive disability, varied therapeutic goals that are not focused exclusively on increased height, and concerns about potential life-threatening adverse events. Objective: The aim of the study was to formulate recommendations for the use of rhGH in children and adult patients with PWS. Evidence: We performed a systematic review of the clinical evidence in the pediatric population, including randomized controlled trials, comparative observational studies, and long-term studies (>3.5 y). Adult studies included randomized controlled trials of rhGH treatment for ≥6 months and uncontrolled trials. Safety data were obtained from case reports, clinical trials, and pharmaceutical registries. Methodology: Forty-three international experts and stakeholders followed clinical practice guideline development recommendations outlined by the AGREE Collaboration (www.agreetrust.org). Evidence was synthesized and graded using a comprehensive multicriteria methodology (EVIDEM) (http://bit.ly.PWGHIN). Conclusions: Following a multidisciplinary evaluation, preferably by experts, rhGH treatment should be considered for patients with genetically confirmed PWS in conjunction with dietary, environmental, and lifestyle interventions. Cognitive impairment should not be a barrier to treatment, and informed consent/assent should include benefit/risk information. Exclusion criteria should include severe obesity, uncontrolled diabetes mellitus, untreated severe obstructive sleep apnea, active cancer, or psychosis. Clinical outcome priorities should vary depending upon age and the presence of physical, mental, and social disability, and treatment should be continued for as long as demonstrated benefits outweigh the risks.

Original languageEnglish (US)
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Consensus Development Conferences
Prader-Willi Syndrome
Human Growth Hormone
Growth Hormone
Guidelines
Pediatrics
Medical problems
Research
Therapeutics
Pharmaceutical Preparations
Randomized Controlled Trials
Morbid Obesity
Self-Help Groups
Obstructive Sleep Apnea
Informed Consent
Practice Guidelines
Psychotic Disorders
Observational Studies
Registries
Life Style

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Growth hormone research society workshop summary : Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. / Deal, Cheri L.; Tony, Michèle; Hoÿbye, Charlotte; Allen, David B.; Tauber, Maïth́e; Christiansen, Jens Sandahl; Ambler, Geoffrey R.; Battista, Renaldo; Beauloye, Véronique; Berall, Glenn; Biller, Beverly M K; Butler, Merlin G.; Cassidy, Suzanne B.; Chihara, Kazuo; Cohen, Pinchas; Craig, Maria; Farholt, Stense; Goetghebeur, Mireille; Goldstone, Anthony P.; Greggi, Tiziana; Grugni, Graziano; Hokken-Koelega, Anita C.; Johannsson, Gudmundur; Johnson, Keegan; Kemper, Alex; Kopchick, John J.; Malozowski, Saul; Miller, Jennifer; Mogul, Harriette R.; Muscatelli, Françoise; Nergårdh, Ricard; Nicholls, Robert D.; Radovick, Sally; Rosenthal, M. Sara; Sipilä, Ilkka; Tarride, Jean Eric; Vogels, Annick; Waters, Michael J.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 98, No. 6, 06.2013.

Research output: Contribution to journalArticle

Deal, CL, Tony, M, Hoÿbye, C, Allen, DB, Tauber, M, Christiansen, JS, Ambler, GR, Battista, R, Beauloye, V, Berall, G, Biller, BMK, Butler, MG, Cassidy, SB, Chihara, K, Cohen, P, Craig, M, Farholt, S, Goetghebeur, M, Goldstone, AP, Greggi, T, Grugni, G, Hokken-Koelega, AC, Johannsson, G, Johnson, K, Kemper, A, Kopchick, JJ, Malozowski, S, Miller, J, Mogul, HR, Muscatelli, F, Nergårdh, R, Nicholls, RD, Radovick, S, Rosenthal, MS, Sipilä, I, Tarride, JE, Vogels, A & Waters, MJ 2013, 'Growth hormone research society workshop summary: Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome', Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 6. https://doi.org/10.1210/jc.2012-3888
Deal, Cheri L. ; Tony, Michèle ; Hoÿbye, Charlotte ; Allen, David B. ; Tauber, Maïth́e ; Christiansen, Jens Sandahl ; Ambler, Geoffrey R. ; Battista, Renaldo ; Beauloye, Véronique ; Berall, Glenn ; Biller, Beverly M K ; Butler, Merlin G. ; Cassidy, Suzanne B. ; Chihara, Kazuo ; Cohen, Pinchas ; Craig, Maria ; Farholt, Stense ; Goetghebeur, Mireille ; Goldstone, Anthony P. ; Greggi, Tiziana ; Grugni, Graziano ; Hokken-Koelega, Anita C. ; Johannsson, Gudmundur ; Johnson, Keegan ; Kemper, Alex ; Kopchick, John J. ; Malozowski, Saul ; Miller, Jennifer ; Mogul, Harriette R. ; Muscatelli, Françoise ; Nergårdh, Ricard ; Nicholls, Robert D. ; Radovick, Sally ; Rosenthal, M. Sara ; Sipilä, Ilkka ; Tarride, Jean Eric ; Vogels, Annick ; Waters, Michael J. / Growth hormone research society workshop summary : Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. In: Journal of Clinical Endocrinology and Metabolism. 2013 ; Vol. 98, No. 6.
@article{2de4de92473d46dcb20f6915659412fa,
title = "Growth hormone research society workshop summary: Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome",
abstract = "Context: Recombinant human GH (rhGH) therapy in Prader-Willi syndrome (PWS) has been used by the medical community and advocated by parental support groups since its approval in the United States in 2000 and in Europe in 2001. Its use in PWS represents a unique therapeutic challenge that includes treating individuals with cognitive disability, varied therapeutic goals that are not focused exclusively on increased height, and concerns about potential life-threatening adverse events. Objective: The aim of the study was to formulate recommendations for the use of rhGH in children and adult patients with PWS. Evidence: We performed a systematic review of the clinical evidence in the pediatric population, including randomized controlled trials, comparative observational studies, and long-term studies (>3.5 y). Adult studies included randomized controlled trials of rhGH treatment for ≥6 months and uncontrolled trials. Safety data were obtained from case reports, clinical trials, and pharmaceutical registries. Methodology: Forty-three international experts and stakeholders followed clinical practice guideline development recommendations outlined by the AGREE Collaboration (www.agreetrust.org). Evidence was synthesized and graded using a comprehensive multicriteria methodology (EVIDEM) (http://bit.ly.PWGHIN). Conclusions: Following a multidisciplinary evaluation, preferably by experts, rhGH treatment should be considered for patients with genetically confirmed PWS in conjunction with dietary, environmental, and lifestyle interventions. Cognitive impairment should not be a barrier to treatment, and informed consent/assent should include benefit/risk information. Exclusion criteria should include severe obesity, uncontrolled diabetes mellitus, untreated severe obstructive sleep apnea, active cancer, or psychosis. Clinical outcome priorities should vary depending upon age and the presence of physical, mental, and social disability, and treatment should be continued for as long as demonstrated benefits outweigh the risks.",
author = "Deal, {Cheri L.} and Mich{\`e}le Tony and Charlotte Ho{\"y}bye and Allen, {David B.} and Ma{\"i}th́e Tauber and Christiansen, {Jens Sandahl} and Ambler, {Geoffrey R.} and Renaldo Battista and V{\'e}ronique Beauloye and Glenn Berall and Biller, {Beverly M K} and Butler, {Merlin G.} and Cassidy, {Suzanne B.} and Kazuo Chihara and Pinchas Cohen and Maria Craig and Stense Farholt and Mireille Goetghebeur and Goldstone, {Anthony P.} and Tiziana Greggi and Graziano Grugni and Hokken-Koelega, {Anita C.} and Gudmundur Johannsson and Keegan Johnson and Alex Kemper and Kopchick, {John J.} and Saul Malozowski and Jennifer Miller and Mogul, {Harriette R.} and Fran{\cc}oise Muscatelli and Ricard Nerg{\aa}rdh and Nicholls, {Robert D.} and Sally Radovick and Rosenthal, {M. Sara} and Ilkka Sipil{\"a} and Tarride, {Jean Eric} and Annick Vogels and Waters, {Michael J.}",
year = "2013",
month = "6",
doi = "10.1210/jc.2012-3888",
language = "English (US)",
volume = "98",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Growth hormone research society workshop summary

T2 - Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome

AU - Deal, Cheri L.

AU - Tony, Michèle

AU - Hoÿbye, Charlotte

AU - Allen, David B.

AU - Tauber, Maïth́e

AU - Christiansen, Jens Sandahl

AU - Ambler, Geoffrey R.

AU - Battista, Renaldo

AU - Beauloye, Véronique

AU - Berall, Glenn

AU - Biller, Beverly M K

AU - Butler, Merlin G.

AU - Cassidy, Suzanne B.

AU - Chihara, Kazuo

AU - Cohen, Pinchas

AU - Craig, Maria

AU - Farholt, Stense

AU - Goetghebeur, Mireille

AU - Goldstone, Anthony P.

AU - Greggi, Tiziana

AU - Grugni, Graziano

AU - Hokken-Koelega, Anita C.

AU - Johannsson, Gudmundur

AU - Johnson, Keegan

AU - Kemper, Alex

AU - Kopchick, John J.

AU - Malozowski, Saul

AU - Miller, Jennifer

AU - Mogul, Harriette R.

AU - Muscatelli, Françoise

AU - Nergårdh, Ricard

AU - Nicholls, Robert D.

AU - Radovick, Sally

AU - Rosenthal, M. Sara

AU - Sipilä, Ilkka

AU - Tarride, Jean Eric

AU - Vogels, Annick

AU - Waters, Michael J.

PY - 2013/6

Y1 - 2013/6

N2 - Context: Recombinant human GH (rhGH) therapy in Prader-Willi syndrome (PWS) has been used by the medical community and advocated by parental support groups since its approval in the United States in 2000 and in Europe in 2001. Its use in PWS represents a unique therapeutic challenge that includes treating individuals with cognitive disability, varied therapeutic goals that are not focused exclusively on increased height, and concerns about potential life-threatening adverse events. Objective: The aim of the study was to formulate recommendations for the use of rhGH in children and adult patients with PWS. Evidence: We performed a systematic review of the clinical evidence in the pediatric population, including randomized controlled trials, comparative observational studies, and long-term studies (>3.5 y). Adult studies included randomized controlled trials of rhGH treatment for ≥6 months and uncontrolled trials. Safety data were obtained from case reports, clinical trials, and pharmaceutical registries. Methodology: Forty-three international experts and stakeholders followed clinical practice guideline development recommendations outlined by the AGREE Collaboration (www.agreetrust.org). Evidence was synthesized and graded using a comprehensive multicriteria methodology (EVIDEM) (http://bit.ly.PWGHIN). Conclusions: Following a multidisciplinary evaluation, preferably by experts, rhGH treatment should be considered for patients with genetically confirmed PWS in conjunction with dietary, environmental, and lifestyle interventions. Cognitive impairment should not be a barrier to treatment, and informed consent/assent should include benefit/risk information. Exclusion criteria should include severe obesity, uncontrolled diabetes mellitus, untreated severe obstructive sleep apnea, active cancer, or psychosis. Clinical outcome priorities should vary depending upon age and the presence of physical, mental, and social disability, and treatment should be continued for as long as demonstrated benefits outweigh the risks.

AB - Context: Recombinant human GH (rhGH) therapy in Prader-Willi syndrome (PWS) has been used by the medical community and advocated by parental support groups since its approval in the United States in 2000 and in Europe in 2001. Its use in PWS represents a unique therapeutic challenge that includes treating individuals with cognitive disability, varied therapeutic goals that are not focused exclusively on increased height, and concerns about potential life-threatening adverse events. Objective: The aim of the study was to formulate recommendations for the use of rhGH in children and adult patients with PWS. Evidence: We performed a systematic review of the clinical evidence in the pediatric population, including randomized controlled trials, comparative observational studies, and long-term studies (>3.5 y). Adult studies included randomized controlled trials of rhGH treatment for ≥6 months and uncontrolled trials. Safety data were obtained from case reports, clinical trials, and pharmaceutical registries. Methodology: Forty-three international experts and stakeholders followed clinical practice guideline development recommendations outlined by the AGREE Collaboration (www.agreetrust.org). Evidence was synthesized and graded using a comprehensive multicriteria methodology (EVIDEM) (http://bit.ly.PWGHIN). Conclusions: Following a multidisciplinary evaluation, preferably by experts, rhGH treatment should be considered for patients with genetically confirmed PWS in conjunction with dietary, environmental, and lifestyle interventions. Cognitive impairment should not be a barrier to treatment, and informed consent/assent should include benefit/risk information. Exclusion criteria should include severe obesity, uncontrolled diabetes mellitus, untreated severe obstructive sleep apnea, active cancer, or psychosis. Clinical outcome priorities should vary depending upon age and the presence of physical, mental, and social disability, and treatment should be continued for as long as demonstrated benefits outweigh the risks.

UR - http://www.scopus.com/inward/record.url?scp=84878475228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878475228&partnerID=8YFLogxK

U2 - 10.1210/jc.2012-3888

DO - 10.1210/jc.2012-3888

M3 - Article

C2 - 23543664

AN - SCOPUS:84878475228

VL - 98

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -